Loss of GPR3 reduces the amyloid plaque burden and improves memory in Alzheimer’s disease mouse models
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Loss of GPR3 reduced amyloid plaque burden and improved cognition in four mouse models of Alzheimer’s disease, suggesting that GPR3 may be a potential therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structural and molecular interrogation of intact biological systems
Chung, K., Wallace, J., Kim, S.-Y., Kalyanasundaram, S., Andalman, A. S., Davidson, T. J., Mirzabekov, J. J., Zalocusky, K. A., Mattis, J., Denisin, A. K., et al. (2013) · Nature · doi:10.1038/nature12107 · Cited by 2,008
Single App knock-in mouse models of Alzheimer’s disease
Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., Iwata, N., & Saido, T. C. (2014) · Nature Neuroscience · doi:10.1038/nn.3697 · Cited by 1,366
Self-citationAβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400784 · Cited by 986
CLARITY for mapping the nervous system
Chung, K., & Deisseroth, K. (2013) · Nature Methods · doi:10.1038/nmeth.2481 · Cited by 747
Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies
Andersen, K., Launer, L. J., Dewey, M. E., Letenneur, L., Ott, A., Copeland, J. R. M., Dartigues, J.-F., Kragh–Sorensen, P., Baldereschi, M., Brayne, C., et al. (1999) · Neurology · doi:10.1212/wnl.53.9.1992 · Cited by 650
Fratiglioni, L., Viitanen, M., von Strauss, E., Tontodonati, V., Herlitz, A., & Winblad, B. (1997) · Neurology · doi:10.1212/wnl.48.1.132 · Cited by 556
Herzig, M. C., Winkler, D. T., Burgermeister, P., Pfeifer, M., Kohler, E., Schmidt, S. D., Danner, S., Abramowski, D., Stürchler-Pierrat, C., Bürki, K., et al. (2004) · Nature Neuroscience · doi:10.1038/nn1302 · Cited by 391 · cited 2×
“TheAPPDutch (11) transgenic mice were crossed with Gpr3 and Gpr3 mice to obtain APPDutch;Gpr3mice.”
MethodResultTransgenic mouse models of Alzheimer’s disease.
Elder, G. A., Gama Sosa, M. A., & De Gasperi, R. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20159 · Cited by 336
Gender differences in the amount and deposition of amyloidβ in APPswe and PS1 double transgenic mice
Wang, J., Tanila, H., Puoliväli, J., Kadish, I., & Groen, T. V. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.08.009 · Cited by 316
Lessons from a failed γ-secretase Alzheimer trial
De Strooper, B. (2014) · Cell · doi:10.1016/j.cell.2014.10.016 · Cited by 277
Augmented Senile Plaque Load in Aged Female β-Amyloid Precursor Protein-Transgenic Mice
Callahan, M. J., Lipinski, W. J., Bian, F., Durham, R. A., Pack, A., & Walker, L. C. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64064-3 · Cited by 274
Bossers, K., Wirz, K. T. S., Meerhoff, G. F., Essing, A. H. W., van Dongen, J. W., Houba, P., Kruse, C. G., Verhaagen, J., & Swaab, D. F. (2010) · Brain · doi:10.1093/brain/awq258 · Cited by 230
Self-citationTrabzuni, D., Ryten, M., Walker, R., Smith, C., Imran, S., Ramasamy, A., Weale, M. E., & Hardy, J. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07432.x · Cited by 229
Self-citationPietrzak, R. H., Lim, Y. Y., Neumeister, A., Ames, D., Ellis, K. A., Harrington, K., Lautenschlager, N. T., Restrepo, C., Martins, R. N., Masters, C. L., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2476 · Cited by 214
Howlett, D. R., Richardson, J. C., Austin, A., Parsons, A. A., Bate, S. T., Davies, D. C., & Gonzalez, M. I. (2004) · Brain Research · doi:10.1016/j.brainres.2004.05.029 · Cited by 212
Morishima-Kawashima, M., Oshima, N., Ogata, H., Yamaguchi, H., Yoshimura, M., Sugihara, S., & Ihara, Y. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64847-x · Cited by 119 · cited 1×
“To assess the GuHCl-soluble Ab fraction of brains, we used a guanidine-HCl extraction protocol as described in (51).”
Method
Cited by
G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?
Sriram, K., & Insel, P. A. (2018) · Molecular Pharmacology · doi:10.1124/mol.117.111062 · Cited by 1,258
APP mouse models for Alzheimer’s disease preclinical studies.
Sasaguri, H., Nilsson, P., Hashimoto, S., Nagata, K., Saito, T., De Strooper, B., Hardy, J., Vassar, R., Winblad, B., & Saido, T. C. (2017) · The EMBO Journal · doi:10.15252/embj.201797397 · Cited by 793
Self-citationViral vectors for therapy of neurologic diseases
Choudhury, S. R., Hudry, E., Maguire, C. A., Sena-Esteves, M., Breakefield, X. O., & Grandi, P. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.02.013 · Cited by 190
“…of siRNA specific for β-secretase (Nawrot, 2004) or shRNA to knock-down the orphan G protein-coupled receptor that regulates activity of γ-secretase (Huang et al., 2015a), the first and second enzymes, respectively, controlling the proteolysis of APP to produce the neurotoxic amyloid peptides,…”
BackgroundJiang, Q., Jin, S., Jiang, Y., Liao, M., Feng, R., Zhang, L., Liu, G., & Hao, J. (2017) · Molecular Neurobiology · doi:10.1007/s12035-015-9670-8 · Cited by 132
Deregulation of neuronal miRNAs induced by amyloid-β or TAU pathology
Sierksma, A., Lu, A., Salta, E., Vanden Eynden, E., Callaerts-Vegh, Z., D’Hooge, R., Blum, D., Buée, L., Fiers, M., & De Strooper, B. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0285-1 · Cited by 120
Self-citation
Metadata
- Authors
- Huang, Y., Skwarek-Maruszewska, A., Horré, K., Vandewyer, E., Wolfs, L., Snellinx, A., Saito, T., Radaelli, E., Corthout, N., Colombelli, J., Lo, A. C., Van Aerschot, L., Callaerts-Vegh, Z., Trabzuni, D., Bossers, K., Verhaagen, J., Ryten, M., Munck, S., D’Hooge, R., Swaab, D. F., Hardy, J., Saido, T. C., De Strooper, B., & Thathiah, A.
- Venue
- Science Translational Medicine
- Published
- 2015-10-14
- Volume
- 7
- Issue
- 309
- Pages
- 309ra164-309ra164
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2179806338
- Cited by
- 88
- References
- 16
- FWCI
- 6.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.